Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics and Outcomes Research, Optum, Eden Prairie, MN...

Full description

Bibliographic Details
Main Authors: Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
biosimilar pharmaceuticals
febrile neutropenia
filgrastim
granulocyte colony-stimulating factor
retrospective studies
Online Access:https://www.dovepress.com/incidence-of-febrile-neutropenia-during-chemotherapy-among-patients-wi-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/incidence-of-febrile-neutropenia-during-chemotherapy-among-patients-wi-peer-reviewed-article-CEOR

Similar Items